Company Filing History:
Years Active: 2014-2016
Title: Inger Lautrup-Larsen: Innovator in Diabetes Treatment
Introduction
Inger Lautrup-Larsen is a prominent inventor based in Virum, Denmark. She has made significant contributions to the field of diabetes treatment through her innovative work at Novo Nordisk A/S. With a total of 4 patents to her name, Lautrup-Larsen continues to push the boundaries of medical science.
Latest Patents
Lautrup-Larsen's latest patents include groundbreaking advancements in insulin analogs. One of her notable inventions is the "Protease-stabilized insulin analogues," which relates to novel insulin analogs featuring mutations at specific positions in the A and B chains. These analogs exhibit resistance towards protease and offer a method for treating diabetes mellitus. Another significant patent is the "Process for preparing FGF21 with low degree of O-glycosylation." This invention focuses on the expression of FGF21 in specific knockout strains, which significantly reduces O-glycosylation without compromising expression levels.
Career Highlights
Throughout her career, Inger Lautrup-Larsen has been dedicated to advancing diabetes treatment. Her work at Novo Nordisk A/S has positioned her as a key player in the development of innovative therapies. Her patents reflect her commitment to improving the lives of individuals with diabetes.
Collaborations
Inger has collaborated with esteemed colleagues such as Peter Kresten Nielsen and Frantisek Hubalek. These partnerships have further enhanced her research and contributed to the success of her inventions.
Conclusion
Inger Lautrup-Larsen is a trailblazer in the field of diabetes treatment, with a strong portfolio of patents that showcase her innovative spirit. Her contributions continue to impact the medical community and improve patient outcomes.